Nephrotoxicity of selective COX-2 inhibitors.

Abstract

We describe 2 male patients, a 49-year-old with psoriatic arthritis and impaired renal function and a 43-year-old renal transplant recipient, who both sustained a marked decline in glomerular filtration rate in conjunction with a selective inhibitor of cyclooxygenase-2 (COX-2), rofecoxib. In the second patient, acute renal failure necessitated hemodialysis. Both patients made an uneventful recovery. Our report lends further support to the assumption that COX-2 inhibitors, as a class, can be as nephrotoxic as their nonselective predecessors. Therefore, COX-2 inhibitors should be used with caution in renal transplant recipients and in patients with salt depletion and renal insufficiency.

• Authors: A Woywodt, A Schwarz, M Mengel, H Haller, H Zeidler, L Köhler
• Journal: The Journal of rheumatology (J Rheumatol) Vol. 28 Issue 9 Pg. 2133-5 (Sep 2001) ISSN: 0315-162X [Print] Canada
• PMID: 11550988 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Cyclooxygenase Inhibitors
• Lactones
• Sulfones
• rofecoxib

Topics

• Acute Kidney Injury (chemically induced, therapy)
• Adult
• Arthritis, Psoriatic (diagnosis, drug therapy)
• Cyclooxygenase Inhibitors (adverse effects, therapeutic use)
• Follow-Up Studies
• Humans
• Kidney (drug effects)
• Kidney Function Tests
• Kidney Transplantation
• Lactones (adverse effects, therapeutic use)
• Male
• Middle Aged
• Osteoarthritis (diagnosis, drug therapy)
• Renal Dialysis (methods)
• Risk Assessment
• Sulfones